🔗 Share this article

As America proceeds with historic adjustments to its vaccination schedules, an unexpected name appears in a surprising turn: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by expressing skepticism about COVID-19 vaccinations throughout the pandemic and has zeroed in on alleged fatalities after Covid vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Vaccine Schedule

Agency leaders were set to reveal radical revisions to the childhood immunization program earlier this month, bringing the US with the Danish immunization schedule, according to reports – a substantial departure that would place the US at odds with a large portion of the global community with little proof for public health gain. The announcement has been postponed until the coming year.

In place of Vinay Prasad, Tracy Beth Høeg is set to address the audience at the gathering. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the division this year.

Consolidating Power at the FDA

This interim role may indicate a closer partnership between the pharmaceutical and biologics branches as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a greater focus upon dismantling previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for discontinuing specific childhood immunization guidelines in the US so as to align more in line with Denmark, a country with comprehensive healthcare and a population about the population of Wisconsin’s.

To date public appearances, she has persisted in emphasizing on immunizations – traditionally the domain of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Questions Over Expertise

Dr. Høeg has no apparent experience in medication creation, approval processes or leadership, which has been typical for former leaders of the CBER. She has worked at the FDA as a key advisor to the FDA chief and the vaccine center since March.

“She doesn’t seem to have the requisite experience” for leading the drug-regulation department, remarked Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in leading a sizeable institution. She has no expertise in drug approvals.”

Former commissioners of the center would “be deeply familiar with regulatory frameworks and the underlying principles of pharmaceutical innovation”, commented Janet Woodcock. “Objectively, she lacks the sort of resume that former directors who led the center have had.”

The drug center has an immense workload at the FDA, she emphasized.

“Everybody just focuses on the innovative therapies, but the generic drug division clears numerous off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and so forth, and all of those must be supervised,” Dr. Woodcock said. “The responsibility you neglect, that is the part that I always told people is going to come back to haunt you.”

Additionally, a significant management aspect to the position, which manages more than 5,000 personnel. “It is a massive administrative position, if you do it right,” she added.

Response and Contentious Programs

Regarding questions about Dr. Høeg's qualifications and whether this appointment represents more teamwork among agency officials on vaccines, a spokesperson responded that the “concerns stem from flawed premises”.

“Her resume aligns with the responsibilities of her role,” the official stated, pointing to the period Dr. Høeg spent advising the agency head on “drug safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg inherits the commissioner’s controversial expedited review system, a disputed one-day drug-approval program that apparently concerned her preceding directors. “By what process are these drugs being picked for this expedited pathway? Who makes the calls?” Dr. Howard asked. “There’s a lot of confidentiality going on at the regulatory body right now.”

Broadly speaking, he said, “the FDA seems to be moving towards more relaxed rules of all drugs, except for vaccines.”

Public Past Work on Vaccines

Regarding immunizations, Dr. Høeg has a clearer, if concerning, past, Howard observe. She authored a research paper using unverified crowd-sourced reports to assess the rate of heart inflammation after COVID-19 vaccination. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who was said to have modified findings to indicate COVID-19 vaccines are pose a greater threat than they are.

Among her “policy goals” for the new federal leadership encompassed altering regulations for recently developed shots and ending “optional” vaccines, she remarked after the election on a podcast. At the FDA, Dr. Høeg has according to sources proposed excluding young men from receiving COVID-19 vaccines.

“She’s an all-around true believer who commences with her beliefs and reverse-engineers to fit the evidence in a highly misleading, untruthful fashion,” Howard argued.

Gaining Influence and a “Push for Payback”

Høeg became part of other dissenters, {like|